MicaGenix, Inc. Company Profile

MicaGenix, Inc.

2000 West Main Street
Greenfield, Indiana 46140
Phone 317.468.1760
FAX 317.468.1765

www.micagenix.com

CORPORATE MISSION

To be a company of high integrity assisting discovery in selecting new developmental products, reducing developmental costs through innovation and automation.

KEY PERSONNEL

Joseph W. Parton
President
jparton@micagenix.com

Kevin Kerzee PhD
Director of Toxicology
kkerzee@micagenix.com

COMPANY HISTORY

MicaGenix is a contract research organization (CRO) founded in 2002 by Joseph W. Parton, a researcher with 35 years of experience at Eli Lilly Research Laboratories. MicaGenix shares the vision that in time the company will be able to serve completely the pharmaceutical industry’s needs for IND and NDA submission.

CORPORATE HIGHLIGHTS

Currently MicaGenix provides services in three areas:

Mutagenicity work includes Ames, chromosomal aberration, micronucleus and comet assays. All are GLP-compliant and meet International Standard Guidelines (ICH, OECD, FDA and EPA). The comet assay is used early in the discovery process to screen for potential genotoxins. MiniAmes and in vitro micronucleus are also used for screening.
Histopathology services include all routine functions, processing formalin fixed tissues and paraffin embedded tissues, processing frozen tissue, and immunostaining. Automated high capacity histology equipment and trained technicians provide high quality slides and rapid turn-around times.
Regulatory package preparation and review includes, but is not limited to, an independent review of toxicology reports and preparation of regulatory summaries for IND/NDA and other regulatory agencies.